EP8.16 Intra-articular hyaluronidase administration associated with improved 6- and 12-month outcomes following hip arthroscopy for femoroacetabular impingement – A national registry study

Clicks: 14
ID: 330945
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #54 of 444 articles by views in Journal of hip preservation surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 444 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Purpose This study assessed the impact of intra-articular hyaluronidase administration during hip arthroscopy for femoroacetabular impingement (FAI) on post-operative patient-reported outcome measure (PROM) scores. Methods All patients who underwent excision of a FAI lesion recorded in the UK Non-Arthroplasty Hip Registry (NAHR) up to November 2025 were identified. Exclusion criteria included concurrent osteotomy, revision procedure and no available baseline and at least one follow up PROM. Cases were then divided into ‘hyaluronidase’ and ‘no hyaluronidase’ groups. PROMs analysed were iHOT-12, EQ-5D Index and EQ-5D Visual Analogue Scale (VAS). Multivariable regression models were fitted and outcomes at 6 and 12 months were analysed independently on a complete-case basis using robust standard errors, excluding BMI due to low completion rate (47.9%), as well as using multiple imputation of covariates including BMI with m=20 and Rubin’s rule for pooling. Results The ‘hyaluronidase’ group (n=141) demonstrated significantly greater median age (38vs34, p<0.001), a significantly greater proportion of cam lesions (75%vs63%, p=0.002) and a significantly greater proportion of Outerbridge Grade 0 patients (93%vs71%, p<0.001) compared with the ‘no hyaluronidase’ group (n=447). No differences in baseline PROMs, BMI, sex distribution or degree of acetabular cartilage damage was observed (all p>0.05). Complete-case analysis demonstrated significantly greater 12 month iHOT-12 (10.5 [SE 3.9], p=0.0082), 6- (4.8 [SE 1.9], p=0.0104) and 12-month (7.0 [SE 2.7], p=0.0096) absolute EQ-5D VAS score, 6- (5.9 [SE 2.5], p=0.0191) and 12-month (8.2 [SE 3.4], p=0.0174) EQ-5D VAS score improvement and 12 month absolute score (0.103 [SE 0.031], p=0.0012) and 12 month score improvement (0.084 [SE 0.036], p=0.0213) for EQ-5D Index. Imputed analysis demonstrated significant improvement in absolute 12-month EQ-5D Index score with hyaluronidase use (0.084 [SE 0.036], p=0.0213). A non-significant trend towards greater 12-month iHOT-12 score improvement was also noted on complete-case analysis (7.4 [SE 4.3], p=0.0879). Conclusion Results from this study suggest that intra-articular hyaluronidase administration is associated with significantly improved absolute outcomes and score improvement from baseline at 6 and 12 months post-operatively. Results should be interpreted with caution given exclusion of BMI in complete-case analysis and high degree of imputation in imputed analysis.
Reference Key
openalex_W7220366007 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Journal of hip preservation surgery
Year 2026
DOI
10.1093/jhps/hnag043.397
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.